TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28351897
Drug: Sensor-augmented insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensor-augmented insulin pump with PLGM OFF
Study: 24802530
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with adapalene 0.1% gel and ketoconazole 2% cream once daily for 2 weeks
Study: 24802530
Drug: Ketoconazole 2%
Normalized name: KETOCONAZOLE 2% CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 2% cream twice daily for 2 weeks (monotherapy group)
Study: 23331844
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg testosterone undecanoate (n = 10)
Study: 12477584
Drug: rapacuronium 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: rapacuronium 0.25 mg x kg(‐1) i.v. (Group 1)
Study: 12477584
Drug: rapacuronium 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rapacuronium 0.5 mg x kg(‐1) i.v. (Group 2)
Study: 12477584
Drug: rapacuronium 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: rapacuronium 0.75 mg x kg(‐1) i.v. (Group 3)
Study: 7637161
Drug: Flumazenil (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (0.2 mg‐1.0 mg)
Study: 29507124
Drug: Intensive audit
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive audit and feedback with daily-updated team-based data dashboard and weekly in-person review of performance data ('STAT rounds')
Study: 29507124
Drug: Usual audit
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual audit and feedback with ongoing twice-monthly emails with graphical depictions of team performance
Study: 25337035
Drug: RBC transfusion
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC transfusion at a Hb threshold of 8.9 g/dL (liberal group)
Study: 25337035
Drug: RBC transfusion
Normalized name: Ultratag RBC KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBC transfusion at a Hb threshold of 7.3 g/dL (restrictive group)
Study: 12946740
Drug: Alfuzosin 5
Normalized name: alfuzosin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfuzosin 5 mg twice daily
Study: 12946740
Drug: Control/Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control/Standard therapy
Study: 20235087
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral carbohydrate loading; 61.0% compliance in audit group vs 96% in trial group; P < 0.001
Study: 20235087
Drug: Non-opiate postoperative
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-opiate postoperative oral analgesia; 70.0% in audit group vs 99% in trial group; P < 0.001
Study: 12519102
Drug: Oxcarbazepine (OXC)
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxcarbazepine (OXC) at a final dose of 900-2100 mg for 14 days, followed by 7 days without OXC, then 14 days back on OXC.
Study: 344019
Drug: M‐‐M (decreasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐‐M (decreasing daily dose of methadone in two equal doses given 12 hours apart)
Study: 344019
Drug: M‐‐PN (decreasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: M‐‐PN (decreasing daily dose of methadone supplemented by propoxyphene napsylate)
Study: 31096538
Drug: Single-dose rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose rectal indomethacin administration
Study: 31096538
Drug: Double-dose rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose rectal indomethacin administration
Study: 24362706
Drug: CocoaCHOC: 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: CocoaCHOC: 350 mg flavanols per serving
Study: 24362706
Drug: CHOC: 0
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOC: 0 mg flavanols
Study: 9454350
Drug: CHARTWEEL radiotherapy
Normalized name: carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CHARTWEEL radiotherapy to 60 Gy (15 weekly fractions of 1.5 Gy)
Study: 9454350
Drug: Conventional fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fractionated radiotherapy to 66 Gy (5 weekly fractions of 2 Gy)
Study: 8094114
Drug: Gentamicin 4
Normalized name: gentamicin 40 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 4 mg/kg once daily (OD)
Study: 8094114
Drug: Gentamicin 1.33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 1.33 mg/kg three times daily (MD)
Study: 31856887
Drug: Twice-daily nebulised
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily nebulised hypertonic saline (HTS 6%) with standard care
Study: 31856887
Drug: Carbocisteine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbocisteine (750 mg three times per day until visit 3, reducing to 750 mg twice per day) with standard care
Study: 31856887
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of twice-daily nebulised HTS and carbocisteine with standard care
Study: 29373476
Drug: MEDI8897 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI8897 50 mg
Study: 23025349
Drug: Prolonged-release oxycodone/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release oxycodone/naloxone (OXN PR) tablets (20/10 mg) with slow, medium, and fast dissolution rates.
Study: 23025349
Drug: Prolonged-release oxycodone/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged-release oxycodone/naloxone (OXN PR) tablets (20/10 mg) with varying dissolution rates.
Study: 20595477
Drug: IV-ibuprofen 400
Normalized name: Suprofen
DrugBank: Suprofen (DB00870)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV-ibuprofen 400 mg every 6 hours for 72 hours
Study: 8863236
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human GH (rhGH, 0.2 mg/kg/d)
Study: 1321655
Drug: Flunarizine 10
Normalized name: flunarizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine 10 mg
Study: 6547612
Drug: Intrathecal cinchocaine
Normalized name: cinchocaine
DrugBank: Cinchocaine (DB00527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal cinchocaine with morphine hydrochloride 2.5 mg
Study: 3453169
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care (SC) treatment
Study: 3453169
Drug: Referred care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referred care (RC) treatment
Study: 29251700
Drug: Low Molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Molecular Weight Heparin (LMWH) 30 mg BID
Study: 29251700
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg BID
Study: 23913744
Drug: Prior ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prior ketoconazole therapy
Study: 21939418
Drug: Once-weekly recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly recombinant factor VIII prophylaxis, with up to two rescue doses per week
Study: 21939418
Drug: Thrice-weekly prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly prophylaxis
Study: 11991797
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (paretic arm and leg immobilized)
Study: 2655259
Drug: Short-term intravesical
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term intravesical therapy (STIT) with 1% solution of Epodyl, given once per week for 6 weeks
Study: 2655259
Drug: Long-term intravesical
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term intravesical therapy (LTIT) with 1% solution of Epodyl, consisting of STIT followed by an additional dose once a month for 2 years
Study: 2655259
Drug: Short-term intravesical
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term intravesical therapy (STIT) for solitary tumors
Study: 2655259
Drug: Long-term intravesical
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term intravesical therapy (LTIT) for solitary tumors
Study: 875786
Drug: Viloxazine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine (100 mg three times a day)
Study: 875786
Drug: Imipramine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (50 mg three times a day)
Study: 20525780
Drug: 4-mg nicotine
Normalized name: nicotine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mg nicotine lozenge with behavioral intervention
Study: 18427418
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (VC: 1 000 mg vitamin C)
Study: 16153930
Drug: Aspirin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (150 mg orally 12 and 3 hours before surgery)
Study: 10613576
Drug: Levodopa 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa 5, 10, or 20 mg (for children <40 kg) or 10, 20, or 40 mg (for children ≥40 kg) 3 times a day
Study: 10613576
Drug: Levodopa/carbidopa combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa combination
Study: 7562679
Drug: Standardized sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized sodium diet with water loading (2290 ml in 3 1/2 hr) and competitive videogame stress test
Study: 27801407
Drug: Intravascular laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravascular laser irradiation of blood (daily 25 min sessions for 7 days, 2 MW, 0.63 microns)
Study: 27801407
Drug: Pharmacotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy alone (control group)
Study: 16111588
Drug: Alternating triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating triple therapy (ATT)
Study: 10819233
Drug: Erythromycin 400
Normalized name: ERYTHROMYCIN 400 mg in 5.2 g TOPICAL POWDER [API E.M ERYTHROMYCIN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 400 mg orally three times a day for 1 week
Study: 10819233
Drug: Erythromycin 200
Normalized name: ERYTHROMYCIN 200 mg in 2 g TOPICAL POWDER [API E.M. Erythromycin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 200 mg orally three times a day for 4 weeks
Study: 10819233
Drug: Intravenous erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous erythromycin 10 mg x kg(‐1) x h(‐1)
Study: 7038165
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of sulfisoxazole
Study: 7038165
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of sulfisoxazole
Study: 7038165
Drug: trimethoprim 160
Normalized name: trimethoprim 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: trimethoprim 160 mg and sulfamethoxazole 800 mg
Study: 7038165
Drug: trimethoprim 320
Normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: trimethoprim 320 mg and sulfamethoxazole 1,600 mg
Study: 31319590
Drug: Cod protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cod protein hydrolysate (CPH) 2.5 g daily for 6 weeks
Study: 27717236
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 28,000 IU once weekly for 24 weeks
Study: 22949149
Drug: High-dose (≥
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose (≥ 30 Gy) thoracic radiation (n = 38)
Study: 22949149
Drug: Lower-dose (<
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose (< 30 Gy) thoracic radiation combined with anthracycline (n = 24)
Study: 22949149
Drug: Higher thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher thoracic radiation dose
Study: 15749317
Drug: Cefuroxime administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime administered intravascularly as a bolus dose of 1.5 g
Study: 8508193
Drug: Carbohydrate (CHO)
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate (CHO) condition with increased carbohydrate intake from 5.8 to 8.8 g kg‐1 BW, supplemented with a 16.5% glucose polymer solution.
Study: 3691011
Drug: Unflavored oral
Normalized name: potassium bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unflavored oral suspension (20 mg/mL)
Study: 3691011
Drug: Tablets (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets (two 200-mg tablets)
Study: 3691011
Drug: Flavored and
Normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavored and unflavored carbamazepine suspensions
Study: 30557965
Drug: Low-dose MDCT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose MDCT (ldMDCT)
Study: 30557965
Drug: Standard-dose MDCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose MDCT (sdMDCT)
Study: 27420732
Drug: Low-Level Laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Level Laser Therapy (LLLT) with a 940 nm diode laser, energy of 4 J/cm² applied to one side immediately after surgery
Study: 25142813
Drug: Edaravone (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone (intravenous 30 mg twice per day for 2 weeks)
Study: 17873681
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus rivastigmine
Study: 17873681
Drug: Rivastigmine plus
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine plus fluoxetine
Study: 10520836
Drug: i.v. pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. pantoprazole (20, 40, 80, or 120 mg)
Study: 10520836
Drug: i.v. pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. pantoprazole (80 and 120 mg)
Study: 10520836
Drug: i.v. famotidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. famotidine (20 mg)
Study: 23085503
Drug: Sertraline (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (initial dose of 50mg once daily, with dose escalation to a maximum of 200mg)
Study: 23085503
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching placebo to sertraline)
Study: 17468863
Drug: Tegaserod 6
Normalized name: tegaserod 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 6 mg, twice daily
Study: 17468863
Drug: Tegaserod 6
Normalized name: tegaserod 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 6 mg, twice daily plus esomeprazole 40 mg, once daily
Study: 17468863
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg, once daily
Study: 14735174
Drug: Infusion topotecan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion topotecan
Study: 11504276
Drug: FFR‐rFVIIa (0.01,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFR‐rFVIIa (0.01, 0.02, 0.05, 0.08, 0.12, 0.18, 0.27, or 0.40 mg/kg body weight)
Study: 1983508
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH) Fragmin
Study: 1983508
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin Calciparin
Study: 304126
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (354 patients)
Study: 31842969
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM), 10 g/packet, twice daily for 2 weeks
Study: 31842969
Drug: CM placebo,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM placebo, 10 g/packet, twice daily for 2 weeks
Study: 15264186
Drug: postdilution HDF,
Approvals — FDA: no, EMA: no, PMDA: no
Description: postdilution HDF, 20 L, with FX80
Study: 15264186
Drug: predilution HDF,
Approvals — FDA: no, EMA: no, PMDA: no
Description: predilution HDF, 20 L, with FX80
Study: 15264186
Drug: predilution HDF,
Approvals — FDA: no, EMA: no, PMDA: no
Description: predilution HDF, 60 L, with FX80
Study: 11578788
Drug: Atorvastatin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin plus vitamin C and vitamin E
Study: 9745160
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: DeNol 120 mg, amoxicillin 500 mg and metronidazole 250 mg four times a day orally for 14 days
Study: 9745160
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: omeprazole 20 mg plus clarithromycin 500 mg twice a day and amoxicillin 500 mg four times a day for 14 days
Study: 9745160
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: omeprazole 20 mg, clarithromycin 250 mg and metronidazole 500 mg twice a day for seven days
Study: 7990079
Drug: Angiotensin II
Normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Angiotensin II (5 ng/kg/min) infusion for three hours
Study: 3198000
Drug: ICS 205-930,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS 205-930, 20 mg
Study: 3198000
Drug: ICS 205-930,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS 205-930, 10 mg
Study: 30213849
Drug: 89Zr-deferoxamine-ZEGFR:03115 (2.4-3.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: 89Zr-deferoxamine-ZEGFR:03115 (2.4-3.6 MBq, 2 μg) co-injected with 10 μg of nonlabeled ZEGFR:03115
Study: 30213849
Drug: 18F-aluminium fluoride-NOTA-ZEGFR:03115
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18F-aluminium fluoride-NOTA-ZEGFR:03115 (12 μg, 1.5-2 MBq/mouse)
Study: 25319131
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment (US) at 1 MHz, intensity of 1.5 W/cm², continuous mode, applied five times a week for 2 weeks
Study: 25319131
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) at 0.8 J/cm² with 905 nm wavelength, applied five times a week for 2 weeks
Study: 20921291
Drug: Calcitriol with
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol with lanthanum carbonate (3000 mg/day)
Study: 20921291
Drug: Calcitriol with
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcitriol with sevelamer carbonate (7200 mg/day)
Study: 15127672
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics as recommended by National Institute for Clinical Excellence guidelines
Study: 3898818
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg at night (hs)
Study: 3898818
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily (bid)
Study: 29468383
Drug: Oral levocarnitine
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levocarnitine solution (50-100 mg/kg/day)
Study: 29468383
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (oral hydrochlorothiazide, enalapril, spironolactone; digoxin for NYHA grade IV; dopamine and dobutamine for intractable heart failure; metoprolol when cardiac function restored to NYHA grade II-III)
Study: 22331280
Drug: Experimental muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental muscle pain (induced by intramuscular injections of hypertonic (6%) saline)
Study: 22331280
Drug: Control (isotonic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (isotonic (0.9%) saline injections)
Study: 20565454
Drug: IK-1001 (Na2S)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IK-1001 (Na2S) 0.005-0.20 mg kg(-1), i.v., infused over 1 min
Study: 17077114
Drug: Subtenon injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtenon injection of triamcinolone acetonide (TA) before laser grid pattern photocoagulation (G‐PC)
Study: 17077114
Drug: Laser grid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser grid pattern photocoagulation (G‐PC) without TA injection
Study: 17077114
Drug: Subtenon injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subtenon injection of triamcinolone acetonide (TA) before G‐PC
Study: 15995772
Drug: Periocline administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periocline administered subgingivally at baseline and weeks 1 to 4
Study: 11955734
Drug: Combined radiotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined radiotherapy and adjuvant chemotherapy (9 weekly cycles of 24-h infusional chemotherapy: 20 mg/m² cisplatin, 2,200 mg/m² 5-fluorouracil, and 120 mg/m² leucovorin) after RT
Study: 11955734
Drug: Radiotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy alone (35-40 fractions, 1.8-2.0 Gy/fraction/day, 5 days/week, total dose 70-72 Gy)
Study: 8568015
Drug: Nefazodone single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone single daily doses (5-500 mg)
Study: 8568015
Drug: Nefazodone multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone multiple daily doses (5 mg or 10 mg 3 times a day to a maximum of 500 mg 3 times a day)
Study: 8568015
Drug: Nefazodone maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone maximum tolerated level (up to 1350 mg total daily dose)
Study: 97474
Drug: Monthly interviews
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly interviews
Study: 23444007
Drug: Free drug
Normalized name: sumatriptan 6 MG per 0.5 ML Needle-Free Drug Delivery System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free drug samples
Study: 16778712
Drug: Caffeine 300
Normalized name: caffeine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 300 mg/d for 11 days
Study: 16778712
Drug: Fluvoxamine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvoxamine (50 mg single oral dose)
Study: 12959287
Drug: Tablet (155
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet (155 mg rac‐hydroxychloroquine)